Navigation Links
Pharmaxis Aridol Approved for Sale in Switzerland
Date:10/19/2008

SYDNEY, Australia, Oct. 19 /Xinhua-PRNewswire-FirstCall/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that it had received approval to market Aridol from the Swiss therapeutic regulatory agency Swissmedic.

Aridol is indicated for measuring airway hyperresponsiveness and within Europe is now approved in 13 countries - Denmark, Finland, France, Germany, Greece, Ireland, The Netherlands, Norway, Portugal, Spain, Sweden, Switzerland and the United Kingdom.

"Swiss physicians have been some of the earliest adopters of Aridol, pioneering early clinical trials, so I am delighted to have the product approved there" said Pharmaxis CEO Dr Alan Robertson. "This level of innovation has attracted the attention of two multinational Pharma companies who are currently funding studies in Switzerland that utilize Aridol to diagnose asthma and COPD patients who will respond to inhaled corticosteroids".

Aridol will be distributed in Switzerland by Trimedal, a specialist respiratory and allergy pharmaceutical company based in Zurich, Switzerland. It has an extensive network of contacts with pulmonary specialists, allergists and respiratory laboratories that will be critical for the market success of Aridol. Pricing for Aridol in Switzerland is included under an existing reimbursement code so marketing may commence immediately.

A simple-to-use airways inflammation test, Aridol is a dry powder administered to patients' lungs via a small hand-held inhaler. Doctors can use the results of this test to identify airway hyperresponsiveness - a hallmark of asthma. Medications can be adjusted according to the severity of the disease.

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We can not guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.

For more information, please contact:

Alan Robertson, Chief Executive Officer

Tel: +61-2-9454-7200

Email: alan.robertson@pharmaxis.com.au

RELEASED THROUGH:

Australia:

Felicity Moffatt,

Tel: +61-418-677-701

Email: felicity.moffatt@pharmaxis.com.au

United States:

Brandon Lewis,

Trout Group,

Tel: +1-646-378-2915

Email: blewis@troutgroup.com


'/>"/>
SOURCE Pharmaxis Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmaxis Investor Conference Call
2. Pharmaxis Research Programs Highlighted at European Respiratory Society Congress
3. New Pharmaxis Board Appointment
4. Pharmaxis Aridol Authorised for Sale in Germany
5. Pharmaxis First Steps into China
6. Pharmaxis to Apply to Market Bronchitol in Australia
7. Pharmaxis Investor Conference Call
8. Pharmaxis Aridol Gains First Asian Approval
9. Pharmaxis Appoints Portuguese Distributor for Aridol
10. Pharmaxis Closes Share Purchase Plan
11. Pharmaxis Announces Placement of $50 Million and Share Purchase Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... SAN DIEGO , Dec. 8, 2016 /PRNewswire/ ... presented demonstrating the role of the Breast Cancer ... stage, ER+ breast cancer are most at-risk for ... therapy. Data include results from three studies advancing ... provide information related to tumor biology and inform ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... SDK that provide essential device-to-computer interconnect using USB or PCI Express, announced the ... support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits a standard ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... data bioInformatics portal. In response to client demand KbioBox developed a sophisticated “3 ... biodesign program. Both are accessible from KBioBox’s new website, https://www.kbiobox.com/ ...
(Date:12/8/2016)... N.J. , Dec. 8, 2016  Soligenix, ... late-stage biopharmaceutical company focused on developing and commercializing ... an unmet medical need, announced today the long-term ... with SGX942 (dusquetide), a first-in-class Innate Defense Regulator ... in head and neck cancer patients undergoing chemoradiation ...
Breaking Biology Technology:
(Date:12/7/2016)... 7, 2016   Avanade is helping Williams ... teams in history, exploit biometric data in order to ... maintain the competitive edge against their rivals after their ... Avanade has worked with Williams during the 2016 ... data (heart rate, breathing rate, temperature and peak acceleration) ...
(Date:12/6/2016)... , Dec. 6, 2016 Securus ... justice technology solutions for public safety, investigation, corrections ... jointly announced today a five (5) year funding ... agreement to expand the rehabilitation and reentry support ... PEP History Established in 2004, the Prison Entrepreneurship ...
(Date:11/30/2016)... , Nov. 30, 2016 Not many of us realize that we spend ... recovery so we need to do it well. Inadequate sleep levels have been found ... pressure, stroke, diabetes, and even cancer. Maybe now is the best time ... could help them to manage their sleep quality? Continue ... ...
Breaking Biology News(10 mins):